Vero Biotech: Secures $50M in Funding

  • Vero Biotech LLC, an Atlanta, Georgia-based biotechnology company, closed a senior secured term loan of $50m
  • Runway Growth Capital provided the financing
  • Vero Biotech (formerly known as GeNO LLC), a biotechnology company focused on the design, development, and commercialization of next-generation products
  • The company also developed the GENOSYL® Delivery System (GENOSYL DS), a inhaled nitric oxide delivery system approved by the U.S. Food and Drug Administration (FDA)
  • The GENOSYL DS transforms the delivery and use of nitric oxide, a vasodilator proven to play a critical role in the care of patients with adult respiratory distress syndrome
  • The GENOSYL® Delivery System authorized by the U.S. FDA for expanded emergency use access for patients with cardiopulmonary complications
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

BMO Strengthens AI and Quantum Research with New Institute

The new institute will focus on advancing AI technology and quantum computing.Highlights: BMO launches Institute for AI and...

Lloyds Strengthens Leadership with AI Agent in the Boardroom

The British bank integrates artificial intelligence into executive decision-making.Highlights: Lloyds Banking Group introduces an AI agent to its...

Ralio Secures $25M to Strengthen Agentic Payments Platform

Funding aims to enhance features and expand market reach.Highlights: Ralio raises $25M in a funding round.The investment will...

Regulators Brief Banks on Anthropic Cyber Risk Amid Growing Concerns

Regulatory bodies emphasize urgent risks from Anthropic's AI developments.Highlights: Regulators issue warnings about Anthropic's AI-related cyber risks.Financial institutions...